Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab.

@article{Hurwitz2004WoundHI,
  title={Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab.},
  author={Herbert I. Hurwitz and Louis Fehrenbacher and Thomas C. Cartwright and John D Hainsworth and William J Heim and Jordan Berlin and Fairooz F. Kabbinavar and William F. Novotny and Frank A. Scappaticci},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={3702}
}
3702 Background. Bevacizumab [Avastin (BV)] is a humanized monoclonal antibody directed against vascular endothelial growth factor. A recent randomized, double-blinded, Phase III trial showed that the addition of BV to bolus irinotecan, 5-FU, leucovorin (IFL) increased survival compared with bolus IFL alone in subjects with metastatic colorectal cancer (CRC). Since BV is an antiangiogenic agent, we undertook an analysis of wound healing in subjects treated with BV plus bolus IFL and BV plus 5… CONTINUE READING

Similar Papers

Loading similar papers…